SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (2759)3/28/2011 2:13:32 PM
From: Skywatcher  Read Replies (1) | Respond to of 7242
 
another complete disaster with corporates taking over a fantastic company and RUNNING INTO THE GROUND ONCE AGAIN
bizjournals.com



To: richardred who wrote (2759)3/28/2011 9:34:34 PM
From: Glenn Petersen3 Recommendations  Read Replies (7) | Respond to of 7242
 
Starbursting

Breaking up companies is back in fashion


The Economist
Mar 24th 2011

NEW YORK

FOR weeks, speculation has been rife that Pfizer, the world’s biggest pharmaceuticals company, will break itself into pieces, a restructuring move known as the starburst. The firm is considering reducing itself to what Ian Read, its boss, calls its “innovative core” by spinning off not just its four smaller non-pharmaceutical divisions (nutrition, consumer health, animal health and capsule-making) but also its huge “established products” division.

If this happened, reckons Sanford Bernstein, a research firm, Pfizer’s annual revenues would shrink from around $67 billion to at most $40 billion. It would be the most notable example yet of the revival of starbursting. So far this year, firms on the world’s stockmarkets have spun off bits of themselves as separate listed companies worth a total of $92 billion, Citigroup calculates. That compares with $54 billion in all of last year, and if the current rate continues, it will easily beat the pre-crisis record of $234 billion in 2007.

So far this year the biggest such deal has been Fiat’s spin-off of a division that makes lorries and tractors, valued at $18 billion. This is still overshadowed by the largest on record, Altria’s $108 billion spin-off in 2008 of its Philip Morris International cigarette business. America’s largest deal this year is Motorola’s hiving-off of its handset-making business, worth $10 billion. ITT, a serial starburster, recently separated off its defence and information business, and a water company, leaving behind a smallish engineering group. The trend is catching on around the world: Carlos Slim, a canny Mexican billionaire, is spinning off Minera Frisco, the mining arm of his Carso conglomerate, worth $7 billion.

One of the main reasons for the starburst revival is that companies seeking buyers for parts of their business are not getting good offers from other firms, or from private equity. Foster’s, an Australian drinks group, is prepared to sell its wine business but, if no decent offer is forthcoming by May, will spin it off.

Another driving force is the “conglomerate discount”—when stockmarkets value a diversified group at less than the sum of its parts. There is talk that Lufthansa, which Citigroup reckons would in pieces be worth twice the parent company’s market value, may spin off its in-flight catering business. Although the conglomerate discount is not usually as extreme as that, its sharp increase in the past year is one of the main reasons companies are regaining their enthusiasm for spin-offs, says Carsten Stendevad of Citigroup. By comparing conglomerates’ constituent businesses with similar, stand-alone ones, Mr Stendevad calculates that they now trade at a discount of around 9%—more or less where things stood before the crisis of 2008.

That this discount is real seems to be confirmed by the positive stockmarket reaction to the latest starbursts. From 20 days before the announcement of a spin-off to 60 days after, the combined value of the parent and spun-off children has on average outperformed the market by eight percentage points, says Mr Stendevad.

The conglomerate discount is far bigger in America and western Europe than in Asian and emerging economies. This may be because in these countries a big conglomerate with political connections and an understanding of how to operate in a difficult market can spread its expertise across many industries. Indeed, there is a conglomerate premium of 10.9% in Latin America, according to Citigroup. This may be why, in some parts of the world, conglomerates are becoming even more diversified: witness Samsung Electronics, which is moving into pharmaceuticals.

America’s big tech firms are also bucking the starburst trend and diversifying. Oracle, a software giant, has moved into hardware, and Hewlett-Packard, a computer-maker, is expanding further into software and services. Their big corporate customers increasingly want a one-stop shop for their information systems.

There is still plenty to the argument that first caught on in the 1980s that breaking up a conglomerate lets managers focus more effectively on the needs of each of the parts of the sum. Yet nowadays the market is relatively pragmatic in its view of conglomerates. Steven Kaplan, an economist at the University of Chicago Booth School of Business, reckons that “as long as your conglomerate is doing well, you can probably keep it together, but when it doesn’t work, it gets broken up.”

Even so, this year’s surge in spin-offs and the rise in the conglomerate discount certainly suggest that new diversifications are likely to be far outweighed by corporate break-ups. Until, that is, management gurus and investment bankers cook up a new theory to justify conglomerates, and the cycle of integration and disintegration starts all over again.

economist.com



To: richardred who wrote (2759)4/26/2011 12:04:18 PM
From: richardred  Respond to of 7242
 
FWIW-SA on SVNT today.

Savient Pharma: Cheap Biotech Without FDA Approval Risk
1 comment | by: Stone Fox Capital April 26, 2011 | about: SVNT




Savient Pharma (SVNT) - a small cap biotech trading 50% below the 52 week high with an approved FDA drug with blockbuster potential - provides an ideal risk/reward scenario. The approved drug also has orphan status, giving it a 7 year marketing exclusivity.

Naturally, the stock wouldn't still fall into the small cap arena if everybody agreed on the blockbuster potential of Kyrstexxa. The drug is one of the first for gout in over 40 years and provides treatment of chronic gout in adult patients refractory to conventional therapy. It treats an previously untreatable disease, providing for a under-served patient base. This is why many analysts and investors are high on SVNT and the blockbuster potential of the drug.

While some in the analyst community disagree over the potential of Kyrstexxa, the major reason for the low stock valuation is that the previous management team made a huge mistake in attempting to auction the company off after obtaining the expected FDA approval of the gout drug last year. This mistake is amongst a litany of other blunders over the last couple of years.

At the time of FDA approval, management reckoned that the company would be more valuable if, instead of spending precious resources on developing a sales team, it could leave that task to a big pharma buyer that already had a massive sales force - maybe somebody already working with rheumetologists. In theory, numerous companies could even tap into an existing underutilized and established sales force, therefore not reinventing the wheel at a huge cost. Theories don't always work in the business world and instead it is presumed that companies used the lack of an established sales force against SVNT in negotiations.

However, those negotiations collapsed and the stock quickly followed. SVNTs stock swooned from $23, eventually falling to the $9 level after the failed auction. Clearly irrational considering the stock traded near $15 before the FDA approval. Was the company's valuation completely reliant on a buyout? An approved orphan drug that meets a desperate need surely has value beyond any such transaction.

As misaligned as the previous management team was, they did an exceptional job in preparing for the launch of this drug with or without a buyout. Even though the auction failed last October, the drug launched on December 1st and had the company had a salesforce in training by January - just in time for the hiring of industry veteran, Eli Lilly & Co (LLY) executive and former ImClone Systems CEO. John Johnson brought immediate credibility to the company, though the stock languished at its lows for the next couple of months.

Currently, as the company comes close to reporting Q1 results, the stock has gotten a bid and is now approaching the $11 level. Remember, the stock is still down $4 since gaining FDA approval and adding a very experienced CEO - one who (it should be noted) successfully sold his last company to a big pharma giant. Hmmm....

Q1 results reported on May 5th will be instrumental in obtaining a higher valuation. Revenue in the $2-3M range could show that the drug is on the way, thus providing SVNT with the ability to negotiate on a firm footing. This time, offer a fair price or the company will clearly go it alone.

Analysts have major disagreements over the peak revenue estimate and it ostensibly comes down to differences of opinions on the potential patient population. See the below excerpts from a Reuters article from last month. Even the bullish analysts undercut management estimates, but they still favor a positive outcome for the stock. Leerink Swann remains as bearish as ever.

Via Reuters DealTalk:

Savient says there are about 170,000 Americans suffering from severe refractory gout. U.S. health regulators estimate this at about 100,000 patients, with the total gout patients numbering more than 2 million.

[..]

"Even if they have 10,000 patients on the drug, that's $600 million right there, which is their current valuation," Roth Capital Partners' analyst Andrew Vaino said, though he estimates a target population of about 45,000 patients.

[...]

"I am still maintaining my estimate of 56,000 patients," said Global Hunter's Lee, who believes the stock is highly undervalued.

[...]

Analyst Joseph Schwartz of Leerink Swann sees the drug fetching a maximum of $500 million in sales. "This is the absolute maximum if everything goes right. If four to five thousand rheumatologists in the United States each put their patients on this drug and they stay on for a year, that would suggest $500 million in the United States," he said.

In summary, SVNT remains a speculative biotech but not nearly as risky considering that it already has FDA approval. This should cap the downside risk, but the upside has lots of potential even if the company doesn't meet managements estimates.

Disclosure: I am long SVNT in client and personal accounts.
seekingalpha.com